Fatty Acid Synthase Inhibitor G28 Shows Anticancer Activity in EGFR Tyrosine Kinase Inhibitor Resistant Lung Adenocarcinoma Models

Epidermal growth factor receptor (EGFR) tyrosine kinases inhibitors (TKIs) are effective therapies for non-small cell lung cancer (NSCLC) patients whose tumors harbor an EGFR activating mutation. However, this treatment is not curative due to primary and secondary resistance such as T790M mutation i...

Descripción completa

Detalles Bibliográficos
Autores principales: Polonio-Alcalá, Emma, Palomeras, Sònia, Torres-Oteros, Daniel, Relat, Joana, Planas, Marta, Feliu, Lidia, Ciurana, Joaquim, Ruiz-Martínez, Santiago, Puig, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281741/
https://www.ncbi.nlm.nih.gov/pubmed/32438613
http://dx.doi.org/10.3390/cancers12051283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281741/
https://www.ncbi.nlm.nih.gov/pubmed/32438613
http://dx.doi.org/10.3390/cancers12051283

Ejemplares similares